Market Overview

Bristol-Myers Squibb Enters 3-Year Agreement with Reckitt Benckiser Group for Over-the-Counter Medicines

Share:
Related BMY
Chardan Initiates Asterias Biotherapeutics At Buy On Potential Cell Therapy Competitiveness
Inovalon And Bristol-Myers Squibb Strike Deal To Focus On Real World Outcomes & Value-Based Contracting Initiatives
3 Stories To Watch At The Year's Biggest Cancer Conference (Investor's Business Daily)

Bristol-Myers
Squibb Company (NYSE: BMY) today announced it has entered into a
three-year collaboration agreement with Reckitt Benckiser Group plc
(OTC: RBGLY) for several of its over-the-counter medicines currently sold
across Latin America, primarily in Mexico and Brazil.

Under the terms of the collaboration agreement, Reckitt Benckiser will
pay Bristol-Myers Squibb an upfront payment in the amount of $438
million for the exclusive rights to sell, distribute and market the
following medicines for a three-year period: Picot, an antacid, Tempra,
a pain reliever and fever reducer, Micostatin, an antifungal, and
Graneodin, a cough and cold medicine, sold primarily in Mexico; and
Dermodex, an anti-rash cream, Luftal, an anti-gas medicine, and

See full press release

Posted-In: News Guidance Contracts Management

 

Related Articles (BMY)

View Comments and Join the Discussion!